Addressing implementation challenges during guideline development – a case study of Swedish national guidelines for methods of preventing disease by unknown
Richter-Sundberg et al. BMC Health Services Research  (2015) 15:19 
DOI 10.1186/s12913-014-0672-4RESEARCH ARTICLE Open AccessAddressing implementation challenges during
guideline development – a case study of Swedish
national guidelines for methods of preventing
disease
Linda Richter-Sundberg1,2*, Therese Kardakis1,2, Lars Weinehall1, Rickard Garvare3 and Monica E Nyström1,2Abstract
Background: Many of the world’s life threatening diseases (e.g. cancer, heart disease, stroke) could be prevented
by eliminating life-style habits such as tobacco use, unhealthy diet, physical inactivity and excessive alcohol use.
Incorporating evidence-based research on methods to change unhealthy lifestyle habits in clinical practice would
be equally valuable. However gaps between guideline development and implementation are well documented,
with implications for health care quality, safety and effectiveness. The development phase of guidelines has been
shown to be important both for the quality in guideline content and for the success of implementation. There are,
however, indications that guidelines related to general disease prevention methods encounter specific barriers
compared to guidelines that are diagnosis-specific. In 2011 the Swedish National board for Health and Welfare
launched guidelines with a preventive scope. The aim of this study was to investigate how implementation challenges
were addressed during the development process of these disease preventive guidelines.
Methods: Seven semi-structured interviews were conducted with members of the guideline development
management group. Archival data detailing the guideline development process were also collected and used in
the analysis. Qualitative data were analysed using content analysis as the analytical framework.
Results: The study identified several strategies and approaches that were used to address implementation challenges
during guideline development. Four themes emerged from the analysis: broad agreements and consensus about
scope and purpose; a formalized and structured development procedure; systematic and active involvement of
stakeholders; and openness and transparency in the specific guideline development procedure. Additional factors
concerning the scope of prevention and the work environment of guideline developers were perceived to influence
the possibilities to address implementation issues.
Conclusions: This case study provides examples of how guideline developers perceive and approach the issue of
implementation during the development and early launch of prevention guidelines. Models for guideline development
could benefit from an initial assessment of how the guideline topic, its target context and stakeholders will affect the
upcoming implementation.
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Non-communicable diseases, such as cancer, cardiovas-
cular disease and diabetes are responsible for 60% of all
deaths globally, killing roughly 35 million people each
year. The WHO estimates that over a third of all cancer
cases and up to 80% of heart disease, stroke, and type 2
diabetes cases could be prevented by eliminating known
risk factors, such as tobacco use, unhealthy diet, phys-
ical inactivity and the harmful use of alcohol [1]. With
evidence-based research on how to successfully encour-
age healthy lifestyle habits, much could be gained, espe-
cially if these recommendations could be incorporated
into guidelines and clinical care practice. Although the
process of collecting, compiling and transferring re-
search evidence into practice in health care settings is
challenging, it is imperative to the provision of effective,
safe and equitable health care [2,3]. This is particularly
true in the fields of health promotion and disease pre-
vention [4].
One way to facilitate the use of evidence in clinical
practice is the development of clinical practice guidelines,
hereafter referred to simply as ‘guidelines’. Guidelines are
defined as “statements that include recommendations
intended to optimize patient care that are informed by a
systematic review of evidence and an assessment of the
benefits and harms of alternative care options” [5]. The
principles for developing guidelines have evolved since
the 1990s, strongly influenced by values and advances
of the evidence-based medicine movement [6]. Guide-
lines are now being developed at international, national
and local levels [7]. The Cochrane Collaboration and
the National Institute for Health and Care Excellence
(NICE) are examples of organizations that have a long
experience of collecting and assessing evidence (which
includes both cost of care and health outcomes) to support
decisions regarding safe and effective medical and public
health interventions [8].
Thus, guidelines are increasingly seen as an effective
means to improve health care practices. There are signs of
an increased emphasis on both pace and quality guideline
development in the past decade, which is exemplified by
the emergence of guideline clearing houses (e.g. http://
www.guideline.gov/), national programs (Scottish Intercol-
legiate Guidelines Network) and societies (Guidelines
International Network) [9-11].
Scholars have argued that much is to gain if imple-
mentation issues are considered early in the guideline
development cycle [3]. However, knowledge regarding
how guideline developers might address implementation
issues is, so far, a relatively unexplored topic in the im-
plementation literature. This study aims to investigate
how implementation issues were addressed by the devel-
opers of Swedish national disease prevention guidelines
during development and early launch phases.Guideline development can be divided in six phases:
prioritizing topics, refining the subject area, assembling
development groups, identifying and assessing evidence,
translating evidence into clinical practice guidelines and
finally reviewing and updating guidelines [12]. Research
examining quality of guideline development points to
the importance of rigour in the development process,
the identification of a target audience, the involvement
of health professionals and targeted populations, and the
attention to procedures for priority setting and the
decision making process [9,13-17].
Several international collaborative initiatives, aiming to
increase quality of guideline development, have been
undertaken during the last decade (e.g. AGREE Consor-
tium, GRADE working group) [18-21]. The Appraisal of
Guidelines Research and Evaluation Protocols I & II
(AGREE) was launched in Spring 2000 to improve guide-
line quality by providing a generic instrument to assess
the guideline development process [20,22]. The AGREE
domains have also been associated with the degree of
guideline implementation [23]. The instrument includes
six domains: 1) Scope and purpose; 2) Stakeholder
involvement; 3) Rigour of development; 4) Clarity of
presentation; 5) Applicability; and 6) Editorial inde-
pendence. High quality guidelines, as defined by the
AGREE protocol, are characterized by their clarity in
scope, recommendations and descriptions of target users;
high stakeholder involvement during development; rigor
of development; and by addressing application issues [23].
Despite considerable investment in developing and
disseminating effective guideline recommendations these
documents have shown limited influence on health
professionals’ behaviour and practice [24-26]. A range
of factors appear to impact the use of guidelines in
clinical practice [3,24,26,27]. Guideline characteristics
[28,29], chosen strategies for implementation and diffu-
sion [2,30,31], and attitudes and motivation of health
professionals [24,32] have for example been shown to
affect the outcome of the implementation process. The
quality of the guideline (e.g. strength of evidence) and
the guideline development procedure have also been
identified as key factors for increasing guideline cred-
ibility and usage [3,26]. Grol and Wensing [33], p.59
suggest that barriers to increasing evidence-based health
practices relate to the innovation itself (e.g. advantages in
practice, feasibility, credibility, accessibility, attractiveness),
the individual professional (e.g. awareness, knowledge,
attitude, motivation to change), the patient (e.g. know-
ledge, skills, health condition, attitude, compliance), the
social context (e.g. culture of the network, collaboration,
leadership), the organizational context (e.g. organization
of care processes, resources, structures) and the economic
and political context (e.g. financial arrangements, regu-
lations, policies).
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Guidelines which focus on health promotion and/or
disease prevention have been in use since the 1980s.
Organizations such as the Canadian Task Force on the
Periodic Health Examination and the U.S. Preventive
Services Task Force, have worked to compile scientific
evidence regarding how health services can more effect-
ively engage in disease prevention [34,35]. The National
Institute for Health and Care Excellence (NICE) in the
UK has pioneered work in this field and has suggested a
conceptual framework for addressing social, economic,
psychological and biomedical determinants of health
and disease among individuals and populations. Their
work seeks to understand the casual mechanisms of dis-
ease patterns and to utilize a broad approach in public
health efforts [36].
Prevention guidelines, in particular, encounter numer-
ous challenges in relation to implementation and use
[4]. The early phases of guideline development, such as
defining target populations and finding and interpreting
the power of evidence, have proven to be particularly
difficult, [4]. To be specific, disease prevention guide-
lines are often built on population-based data, which are
typically generic in nature and thus relevant to a range
of different disease states. General conclusions about
lifestyle recommendations may not be relevant for the
specific situation of every individual [4,37,38]. Personal
preferences and attitudes towards health promotion
among health professionals and patients also affect the
use of health-promotion guidelines [32,39].
The systems for decision-making and evidence ap-
praisal in health care are to a large extent similar for
both general disease prevention and treatment of spe-
cific issues, but the two knowledge areas differ in funda-
mental matters and the match is not ideal. Evidence-
based medicine predominantly uses randomized control
trials (RCT) for identifying best practices. Community-
level interventions may show significant effects in large
populations, but small effects on the individual level. In
preventive studies, many RCTs lack adequate power,
leading to relatively weak evidence and uncertainty about
outcomes [4,40,41].
Differences in the basic principles of evidence-based
medicine and evidence-based public health practices have
been shown for example in the span of the evidence. Public
health operates on several levels, which include individual,
group, community and societal practices/structures, while
medical practice is based on biomedical traditions. The
breadth of public health evidence affects guideline devel-
opment during the search for evidence (e.g. difficulties to
find evidence in conventional databases) and the grading
of evidence (e.g. combining the principles of assessing
the standard evidence in medical science (i.e. RCTs)
with the behavioural and social sciences research studiesfocusing on questions that often do not lend themselves
to trial research designs) [40]. Transparent decision
models to support the appraisal of public health inter-
ventions have been suggested as a means to guide health
care decision makers [8].
The National Board for Health and Welfare (NBHW)
is the government agency responsible for the develop-
ment of national guidelines in Sweden. To better pro-
mote the implementation of new medical technologies
and evidence-based treatments NBHW designed a new
model for guideline development in the early 2000s that
went beyond evidence compiled by experts. The model
included consultations with health care providers,
recommendations based on feasibility in the documen-
tation, and prioritization of recommendations based
on the compiled, trilateral, evaluation of scientific evi-
dence, health-economic evaluations and ethical consid-
erations (see Figure 1). The formalized procedure for
guideline development is described in detail at the
NBHW website [42]. The NBHW guideline develop-
ment policy is intended to create a balance between
three dimensions; severity of the condition, efficacy of the
method and cost-effectiveness of the method. The NBHW
guideline development process deals with problems
(e.g. how to increase transparency and inclusiveness in
panels and how secure rigour and quality in its method-
ology) identified also by other guideline developers. The
model adopts similar types of solutions as those utilized
by larger guideline developers in other countries
[36,43-46]. For example, NICE has addressed issues on
systematic use of research evidence and assessing cost-
effectiveness and stakeholder involvement. These are
fundamental guideline development features that also
are included in the NBHW model [42,46]. The NBHW
guideline development model is frequently updated to
improve and enhance guideline quality in guideline
production [42].
The NBHW guideline development process follows a
transparent methodology (documented in methods man-
uals) that states how evidence should be collected, assessed
and transformed into recommendations. The priority of an
intervention is set by assessing the gravity of the related,
unhealthy lifestyle practice (e.g. smoking) and expected
benefits and costs of the intervention (e.g. advanced
counselling) based on scientific evidence and evalua-
tions of cost-effectiveness [47].
The NBHW model was based on the premise that
Swedish health care, by law, is considered to be a re-
sponsibility of all the county councils and municipalities
in the country. The Swedish county councils also have
the primary responsibility for guideline implementation
at the regional level and for deciding the level of re-
sources which will be made available in clinical practice.
Target users of guidelines were primarily health care
Figure 1 Guideline development model at the NBHW.
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tients treated for other reasons.
Since 2003, NBHW has developed 15 national guide-
lines, mainly focusing on treatment of medical condi-
tions. Several of these guidelines indicate that changes in
unhealthy habits are important. However, they do not
discuss which methods are best suited for this purpose.
In 2008, NBHW began the process of developing guide-
lines for disease prevention – the National Guidelines
for Methods of Preventing Disease in Clinical Practice,
hereafter called Disease Prevention Guidelines. These
guidelines focused on four lifestyle habits: tobacco use,
hazardous use of alcohol, insufficient physical activity
and unhealthy eating habits.
The aim of this study was to investigate how imple-
mentation challenges were addressed during the process
of developing guidelines for disease prevention. These
Disease Prevention Guidelines offered the opportunity
to study both general and prevention specific implemen-
tation challenges, as well as strategies used by govern-
ment agency guideline developers.
Methods
This case study is based on interviews conducted with
guideline developers involved in the creation of the
NBHWs Disease Prevention Guidelines, as well as on
archival data. Data were collected between Oct. 2009
and Sept. 2012.
Data collection
Seven semi-structured interviews were conducted with
the guideline development management group and the
head of the guideline development unit at the NBHW.
Interviews focused on the Swedish model for developing
national guidelines and explored how implementation
challenges were perceived and handled during the guide-
line development process. An interview guide attempted
to capture guideline developers’ experiences and their
thoughts regarding implementation challenges. The guide
also included questions for exploring strategies foraddressing challenges during the guideline develop-
ment process. Examples of interview questions include:
Could you describe the process for developing guide-
lines on disease prevention, from when you started, up
to the present moment? How did the NBHW’s general
guideline development model apply in this specific
case? What do you perceive the major challenges will
be for ensuring that guidelines reach targeted users?
What role should NBHW play in regard to implemen-
tation of the guidelines? Interviews were conducted
with all members of the guideline development man-
agement group and the head of the department of
guideline development at the NBHW. Interviews lasted
from 55 to 95 minutes. They were recorded and tran-
scribed verbatim and respondents were asked to review
the transcripts to identify any necessary corrections.
Additionally, archival data were collected from the
NBHW website (e.g. the final Disease Prevention Guide-
lines document and information sheets), from official
documents (e.g. laws, government bill) and through
personal contacts with the guideline developers at the
NBHW (e.g. formal steering documents concerning the
general guideline development process and the NBHW).
Data analysis
Qualitative content analysis [48] was used to analyse
qualitative data. The analysis procedure was performed
in five steps. First, transcribed data from interviews and
texts in archival data were read through several times to
get a sense of the overall content. Secondly, content that
referred to implementation challenges and strategies (e.g.
barriers and facilitators of implementation, activities and
strategies aimed to promote implementation) was identi-
fied for further analysis. In a third step, text units with
coherent statements (i.e. sentences, sections of text with
coherent content) were coded with a condensed label
intended to capture the essence of meaning. Codes with a
common meaning were then grouped in categories. In a
fourth step the categories with a common meaning were
merged into themes. Finally, the themes were structured
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the AGREE II instrument [22]. The domains reflect
significant aspects of Guideline development and have
implication for their prospect to be implemented in
practice. The themes that were identified in the analysis
process (step II-IV) were organized into one of the six
AGREE domains in a table. The themes that did not fit
the AGREE framework, are described separately in the
results section. Data analysis was performed by two
researchers (LRS, TK). When opinions differed, discus-
sion with a third researcher (MN) was performed to
reach consensus and if consensus could not be reached
the decision was based on the views of the majority.
Ethical considerations
Participation was based on informed consent and was
voluntary. The study was approved by the regional
Ethics Committee at Umeå University, Umeå, Sweden
[Dnr 2011-64-31 M].
Results
Our analysis of the development of the Disease Preven-
tion Guidelines shows that implementation challenges
were identified and addressed by guideline developers.
Several of these activities and approaches i could be
condensed into four themes: 1) Broad agreements and
consensus about scope and purpose; 2) Systematic and
active involvement of stakeholders; 3) Formalized and
structured development procedure; and 4) Openness
and transparency in the specific guideline development
procedure. Two additional factors were perceived as
influencing developers’ choices for addressing implemen-
tation issues; the preventive guideline scope and guide-
line developers workload. Table 1 presents an overview
of the identified strategies organized within the AGREE
domains. Statements from interview respondents and
from the final version of the Disease Prevention Guidelines
are used to exemplify and clarify themes and categories.
Broad consensus about the guidelines scope and purpose
Archival data state that the need for disease preventive
guidelines was initially raised as a political initiative,
based on national public health policy. This policy was
launched by the Swedish Parliament in 2002 and specif-
ically targeted the role and responsibility of the health
service providers to improve their performance in health
promotion [49]. In parallel, the NBHW identified large
regional differences in Swedish health care provider
disease prevention practices. To meet these challenges,
NBHW decided to develop national guidelines that
would focus on disease prevention.
Respondents described how hearings and spoken agree-
ments with a broad range of interest groups (i.e. health
care providers, politicians) were used to identify and settleon a feasible focus and objectives for the Disease
Prevention Guidelines. The developers considered these
collaborations and agreements to be a significant compo-
nent for implementation success, as they prompted a
readiness, both among guideline developers and among
target users, on what the guidelines may come to imply.
“The goal was to reach consensus over the country
about which areas these guidelines should address as
early as possible in the process. To direct health care
in a top-down manner on how they should work. But
guidelines are after all a soft law, there is no support in
the (formal) law. The NBHW cannot give penalties to
health providers who do not adhere to the guidelines.
If we do not collaborate with the users – in a broad
sense – from the very beginning, clinical guidelines
will stay on the bookshelves. If we fail to narrow them
down and to have a realistic scope the main objective
also fails, to reduce disparities across the country and
the differences in the various groups of the population
access to care.” (Guideline developer, Disease Preven-
tion Guidelines).
Systematic and active involvement of stakeholders
Steering documents and respondents described how
different actors were involved in the process during
different stages of the development process (Figure 2).
According to the NBHW guideline development model,
caregivers should be regularly involved during the process.
Respondents described how this was particularly im-
portant in the case of the Disease Prevention Guidelines
as it, unlike diagnosis-related guidelines, has no easily
identified target population.
The Disease Prevention Guideline development in-
volved 70 individuals organized in six operative groups:
the guideline development management group (6), a
prioritization group (25) and four expert groups (39).
The expert groups were staffed based on their expertise
in prevention and one or more of the four life-style
areas. Expertise in the fields of scientific methodology,
health economics, ethics and communication/linguis-
tics were also made available to the guideline develop-
ment group.
Health professionals, experienced in disease prevention
in clinical settings, were involved in the process of priori-
tizing. The task of the prioritizing group was to rank
recommended practices from 1 (highly recommended)
to 10 (not recommended) based on the severity of the
condition, efficacy of the method, and cost-effectiveness.
With the goal of involving a variety of stakeholders, the
developers tried to obtain wide representation in the
prioritization group, equal gender representation, and
accordingly engaged professionals from different parts of
the country, professional groups and knowledge areas. A
majority were also trained researchers. The meetings with
Table 1 Strategies to address implementation challenges during development of the Disease Prevention Guidelines
Framework Theme Category Sub-category
Guideline scope and purpose Broad agreements and consensus
about scope and purpose
Target audience involved in framing the
guideline scope and purpose
Hearings with health-promoting organizations and
politicians, professional groups
Political proposal preceded guidelines with
health-promoting scope
Systematic and active involvement
of stakeholders
Health-promoting hospitals networks used for
piloting scope and identifying target population of
Disease Prevention Guidelines
Formalized and structured
development procedure
Using systematic methodology for identifying
and defining the Disease Prevention Guidelines
concepts and health questions
Formal criteria for initiating CPG-process
Preparatory development process defining concepts
and scope
Systematic methodology in defining guideline health
questions and key concepts
Stakeholder involvement Systematic and active involvement
of stakeholders
Guideline development group included a wide
scope of relevant professional groups and fields
of knowledge
Experts representing: the CPG target area/s; methodology;
communication; ethics; health economics
Health professionals representing: the CPG target area/s;
different parts of the country; different patient groups;
and different parts of the health care system
Involvement of stakeholder throughout the
guideline development process
Meetings and collaboration with health-promoting
organizations, politicians, and professional groups in
the early phases of development
Regional conferences with health providers in the county
councils
Rigour of development Formalized and structured
development procedure
Formalized CPG development procedure Formalized procedure for defining purpose, scope and
concepts
Formalized procedure for searching and assessing evidence
Formalized consensus procedure when there is a lack of
evidence
Formalized procedures are suggested for monitoring,
evaluation and follow- up of Disease Prevention Guidelines
Openness and transparency in Disease
Prevention Guidelines development
procedure
Transparency in methodology Guideline development procedures explicit and overt
Recommendations and the supporting evidence are
clearly connected
Clarity of presentation Openness and transparency in Disease
Prevention Guidelines development
procedure
Clear presentation of guideline development
model
Description of the general Guideline development model
is presented
Description of the Disease Prevention Guidelines
development model and organization is presented
Methodology for collecting evidence is presented
Clear presentation of the Disease Prevention
Guidelines recommendations
Experts in communication involved in the formulation of
Disease Prevention Guidelines
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Table 1 Strategies to address implementation challenges during development of the Disease Prevention Guidelines (Continued)
Links between recommendations and evidence are clear
Applicability Systematic and active involvement
of stakeholders
Target users tested the hypothetical use of the
Disease Prevention Guidelines recommendations
Health professionals hypothetical tested the use of the
Disease Prevention Guidelines in clinical setting
Health care providers hypothetical tested the use of the
Disease Prevention Guidelines in a health care
management setting
Openness and transparency in Disease
Prevention Guidelines development
procedure
Barriers/facilitators for the Disease Prevention
Guidelines application were presented
Facilitating factors for the implementation of the Disease
Prevention Guidelines were sought by target users
Monitoring, evaluation and update of Disease
Prevention Guidelines
Barriers for the implementation of the Disease Prevention
Guidelines were sought by target users
Formalized procedures for monitoring, evaluation and
follow- up of Disease Prevention Guidelines are suggested
Editorial independence Openness and transparency in Disease
Prevention Guidelines development
procedure
Autonomy of Guideline developers The NBHW autonomous government agency
Formalized procedures for seeking and recording possible
competing interests of all members of development group
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Figure 2 Involved stakeholders in different phases of the guideline development.
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participation with a decision process described as an
adopted Delphi-method.
The purpose of involving many people in the develop-
ment process was associated with the implementation
challenge. The network activities aimed to create broad
agreements about the advantages and demarcations of
disease preventing guidelines, as early as possible in the
process. Secondly collaborations aimed to raise awareness
about the upcoming guidelines and to engage influential
actors in the early stages of guideline development. Finally,
by including representatives of many different stakeholder
groups the developers hoped to predict and plan for a
wider range of implementation barriers.
Throughout the development process influential orga-
nizations and networks (e.g. NGOs, public authorities
and a national network of health-promoting hospitals) were
involved through hearings, interviews, and piloting trials.
“By collaborating with the health professional groups
and the national network of health-promoting hospitals
and incorporating them in our development process, in
defining the main purpose and what lifestyle areas we
should include and which we had to exclude, we aimed
to plant a seed of change that would have the opportun-
ity to develop as the guidelines developed. The initial ef-
forts to identify the relevant health questions are crucial
for implementation. And that starts on day one of the
guideline development, with hearings and broad dis-
cussions. We thought ‘implementation’ from the very
beginning.” (Guideline developer, Disease Prevention
Guidelines).
Respondents also described difficulties with involving
the target population in the guideline development
process. Traditionally, NBHW utilized patient/consumer
organizations to recruit target populations (e.g. patients,
public). However, in the case of the development of
Disease Prevention Guidelines, recruitment was difficult
due to the focus on prevention. Respondents indicated
that the target populations’ perspective was, to someextent, advocated by the health professionals serving in
the prioritization group.
During the final stages of guideline development,
potential target users were involved in regional seminars
and referral rounds where stakeholder views and prefer-
ences were sought. These views and preferences led to
changes in the final version of the guidelines. Respon-
dents described how stakeholder groups (e.g. health pro-
viders and representatives from the health promoting
hospitals network) raised different considerations regard-
ing the future use of the guidelines. For example, stake-
holders asked which health professional groups (e.g.
physiotherapists, nurses, GPs, psychologists) would be
responsible for the interventions recommended in the
guidelines. Developers chose not to provide detailed
answers about application of the guidelines, as they felt
this was the most appropriate response in light of health
providers’ independence from national governance.
Respondents also argued that this standpoint stimulated
local engagement and responsibility for the implemen-
tation of the guidelines.
Formalized and structured development procedure
The NBHW guideline development model outlines a
formalized procedure for preparing and completing the
development of guidelines. Respondent comments under-
scored the need for a proscribed process and described
how the definition of key guideline concepts required
a systematic, preparatory procedure, where the basic
concepts and terms were thoroughly scrutinized and
defined. Respondents attributed the clarity of scope,
purpose and concepts as important for encouraging
target user’s motivation, understanding and future
accuracy in guideline usage.
“The concepts of health promotion or disease preven-
tion were not very distinctly defined among us when the
development of the Disease Prevention Guidelines was
initiated. And if we were not clear about these basic
concepts in the very beginning, we acknowledged the
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we or the literature we based the recommendations on
intended. So we put a lot of energy and resources in
defining the concepts and scope of the guidelines.”
(Guideline developer, Disease Prevention Guidelines).
Procedures for searching, assessing evidence and
formulating recommendations were described in the
model and in the final version of the Disease Preven-
tion Guidelines and published on the NBHW website.
A plan for evaluating and updating guidelines was
provided with the final version of the guidelines. The
guideline developers identified the use of systematic,
transparent and scientifically sound methods as an
essential factor for implementation, affecting future
guideline users’ perception of the reliability and trust-
worthiness of the Disease Prevention Guidelines.
Respondents stated that for some conditions/interven-
tions there was a significant lack of evidence for appro-
priate grading approaches (according to GRADE). This
problem was addressed through a formalized consensus
procedure where existing evidence was complemented
with proven, clinical experience.
“It is easier to develop guidelines with a medical scope
since they often include a higher amount of studies that
fit our questions as developers, compared to guidelines
with a preventive scope. It is more difficult when we do
not have a good scientific basis and we have no health
economic data. It is a flaw. Then it may be based on
estimates, which is not optimal. We have handled the
shortcomings of scientific data through developing a
consensus process. We had a need to formalize and
systematize proven experience in any sense.” (Guideline
developer, Disease Prevention Guidelines).
Respondents also described how the structured and
rigorous guideline development process was demanding
for the members of the guideline development groups.
Respondents expressed that that it was a challenge to
educate the participating experts and health profes-
sionals on the development model and follow it through.
Transparency in the disease prevention guideline
development process
Several of the respondents described efforts to provide a
rich description of Disease Prevention Guidelines devel-
opment methods, as well as providing evidence and the
health economic evaluations to clarify the basis for
recommendations. The recommendations were linked to
references and the background material and the final
guideline document was published on the NBHW
website. Respondents felt that these considerations were
important for increasing transparency and reliability in
the development process. Respondents also critiqued
their own performance in the development process
concerning ambiguous instructions to involved expertsand health professionals. Respondents felt, that this issue
provide some explanation for the delay in guideline
completion. The process took five years and was delayed
approximately ten months in relation to the original
completion deadline.
Communications and linguistics experts edited the
final document to strengthen clarity and reduce ambi-
guities. Recommendations were described in summary
form and included brief advice, counselling or qualified
counselling as methods for changing lifestyle. The
recommendations included a brief description of coun-
selling methods, with more detailed descriptions given
in a supplement. The guideline developers stated that
it was very difficult to keep a balance between being
clear and specific and being general enough to preserve
the independence of the Swedish regional health care
providers.
The respondents underscored the value of the regional
conferences as a means for addressing implementation
challenges in the last phase of the guideline development
process. In these conferences, regional health care pro-
viders and guideline developers met and openly assessed
the implications of the Disease Prevention Guidelines.
Some of the respondents stated that the regional confer-
ences increased the health care providers’ awareness and
responsiveness to the final version of the guidelines.
Resource implications and potential implementation
barriers were presented by health care providers during
the final phases of the development process. By asking
health care managers to assess consequences and re-
source implications of guideline implementation (e.g.
educational, technical resources) they hoped to influence
the target users to use of the Disease Prevention Guide-
lines at local, regional and national levels. Thanks to
these regional considerations, a chapter detailing finan-
cial and organizational consequences of guideline imple-
mentation was presented, discussed and included in the
final version of the Disease Prevention Guidelines.
“The NBHW concluded that the guidelines required
(organizational) changes in terms of human resources,
steering documents, organization and reallocation of
resources, education and skills and interaction with
stakeholders within and outside the health sector.” (text
extracted from the Disease Prevention Guidelines).
Respondents also discussed how guideline developers
(including experts and health professionals) were asked
to state their competing interests. Information about all
members of the guideline development group was docu-
mented in the initial phase of the Disease Prevention
Guidelines process and one member was excluded from
the process based on the possibility of editorial depend-
ence. The respondents felt these efforts to ensure editorial
independence, increased guideline credibility, which in
turn would enhance guideline implementation.
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Respondents described the process of disease prevention
guideline development as challenging and explorative
and a pioneering journey. The focus on prevention,
challenged various components of the established model
for guideline development at NBHW, being that is was a
new type of guideline (preventive) that covered a large
field and several topics (four, lifestyle habits). The
generic characteristics of these prevention guidelines
also created challenges relating to the multidisciplinary
audience of guideline users and target population. Respon-
dents described the process of defining the intended
users and target population (i.e. health professionals
and individuals with hazardous lifestyle/s) as long and
complex. Specific attention was given to this issue and
criteria for identifying the target population were devel-
oped and piloted through the health-promoting hospi-
tals network in Sweden.
The long and complex process of guideline develop-
ment was largely undertaken by the 3–4 people in the
guideline development management group. Towards the
end of the process, the workload increased and respon-
dents described this last phase of development as intense
and very demanding. Some respondents concluded that
the strained work conditions led to a decreased focus on
implementation and guideline applicability, thereby chal-
lenging developers’ ability to plan ahead in the process.
Discussion
Several key issues influencing the success or failure of
guideline implementation are settled already during the
guideline development process. It is therefore urgent to
address these issues when planning for guideline devel-
opment. Several basic features (e.g. the purpose of guide-
lines, resource implications, clarity of recommendations)
have been shown to play an important role in guideline
usage [3,22], which suggests that the development phase
offers great opportunities to improve the implementa-
tion of guidelines. How this should actually be carried
out in practice, is a topic that has received less scrutiny.
This case study provides an in-depth look at the
possibilities to address implementation challenges during
development of prevention guidelines. Several activities
and approaches for enhancing the achievement of guide-
line intentions were identified. Four areas for achieving
guideline development success included: broad agree-
ments and consensus about scope and purpose of the
guidelines, a formalized and structured development
procedure, systematic and active involvement of stake-
holders, and openness and transparency in the guideline
development process. In addition, the early involvement
of the target audience and the involvement of a broad
group of stakeholders made hypothetical trials anddiscussions of guideline implementation possible. This
was one aspect of the development process that seemed
to be especially important for prevention guidelines. To
increase trustworthiness and the quality of the guide-
lines, rigorous and transparent methods were used for
sourcing, prioritizing and incorporating information on
health economics and ethics.
The NBHW’s main task is to develop guidelines and
recommendations in a credible way and, through
collaborations, transparency and support, to stimulate
implementation. However, the NBHW is restricted in
its influence, due to a limited mandate as a government
agency among rather autonomous county councils and
municipalities in the Swedish health care system.
To be used, it has been argued that clinical guidelines
need to be established and integrated as a part of other
health care quality improvement processes [50]. This
requires cooperation between guideline developers and
health care’s stakeholders [51] In this case the planning
and development of guidelines involved both a national
authority and the regional and local care providers. Such
integration is possible if consensus on focus and purpose
can be accomplished. Having a dialogue and making
agreements with stakeholders at different levels in the
health services system – from politicians to health care
providers and health professionals, is also a valuable
practice in the development process.
Further, this strategy of broad agreement may have
contributed to raised awareness and motivation among
guideline target users (e.g. health care management) in a
way that boosts health care organizational readiness to
alter their course in the direction of the Disease Preven-
tion Guidelines. This strategy is supported by similar
research. For example, Cabana et al. [24] identified lack
of familiarity, awareness and agreement with guidelines
as significant barriers to guideline adherence among
physicians. Nevertheless the involvement of a large
number of stakeholders, the balancing of integrity with
the NBHW guideline model, and the flexibility intro-
duced by the stakeholders’ involvement, all came at a
cost. The process was described as complex, long and
demanding by the guideline development management
group. This reflects a need to regularly address process
issues, such as the time and resources required in
different development phases and type of complexity
connected to various guideline areas.
The NBHW used its standard guideline development
model with small adjustments to fit the prevention
focus. The unusually complex development process that
respondents found frustrating might reflect difficulties
that come with matching public health interventions to
the prevailing medical evidence system [8,40,41].
The involvement of patients or other target populations
in guideline development is supported by WHO, the
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However, recent studies have shown that methods for in-
creasing target user engagement still need to be improved
[53]. For diagnosis-related guidelines, the Swedish model
systematically involves patient organizations in the
development process. This was not applicable with re-
gard to Disease Prevention Guidelines as the “Patient
Organization of the Not Yet Diseased” does not exist.
Due to its generic focus, the lack of clear stakeholders
and target users may have hindered involvement of
these groups during development. Instead, in the Swedish
context, elected representatives, primarily politically
designated providers, were assumed to take on the role
of representing the public.
Our results are based on a single case study of preven-
tion guideline development in a specific national con-
text. There might be other aspects that need to be
considered in other contexts and other ways of achieving
a more conscious focus on implementation issues and
preparations for implementation.
Conclusions
This case study provides examples of how guideline
developers perceive and approach the issue of imple-
mentation at an early stage in the life-cycle of prevention
guideline development. The study also identifies charac-
teristics of the process of developing guidelines with a
preventive or public health focus. These include the
complexity of addressing implementation issues in this
area and the need for a decision model when addressing
research not based on RCTs. The prevention focus influ-
enced how implementation challenges were perceived and
addressed. We conclude that guideline developers could
benefit from including an assessment of what the specific
focus areas (e.g. preventive, treatment) of guidelines may
imply for their future use and how these areas impact the
support needed for guideline implementation. Another
question that should be explored in future research relates
to how scientific evidence from the field of public health
and preventive medicine should be operationalized and
assessed in the guideline development process.
It seems obvious that societies would benefit from utiliz-
ing available knowledge for addressing major threats to
global health and innovative ways for improving life-style
practices of large populations. But the path from evidence
to changed health practice is an uneven one. Prevention
guidelines might aid this process, but clinical guidelines will
reach their potential only if they are known, adopted and
used by their target groups. By illustrating how specific
implementation challenges were perceived and addressed
throughout different phases of guideline development, this
study can provide some ideas for how to improve guideline
development and support the implementation of preventive
actions in health systems and health care practices.Abbreviations
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